

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marie-Christine BISSERY

Serial No.: Not Yet Assigned

Filed: March 8, 2002

For: A COMBINATION COMPRISING  
COMBRETASTATIN AND  
ANTICANCER AGENTS

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Assistant Commissioner for Patents  
Washington, DC 20231



Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicant brings to the Examiner's attention the documents listed on attached Form PTO-1449. Copies of the listed documents are attached. Applicant respectfully requests that the Examiner consider the documents listed on attached Form PTO-1449 and indicate that they were considered by making an appropriate notation on this form.

This Information Disclosure Statement is being filed with the above-referenced application.

The following are listed on the accompanying PTO-1449 and are in a non-English language:

1. European Patent Publication No. 0 253 738 - The relevance of this document is discussed at page 18 of the specification of the present application.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

2. European Patent Publication No. 0 253 739 - The relevance of this document is discussed at page 18 of the specification of the present application.

3. WIPO Publication No. WO 92/09589 - The relevance of this document is discussed at page 18 of the specification of the present application.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: March 8, 2002

By:   
Ernest F. Chapman  
Reg. No. 25,961

Enclosures  
EFC/FPD/sci